DYN Dyne Therapeutics

Dyne Therapeutics to Present at Jefferies Healthcare Conference

Dyne Therapeutics to Present at Jefferies Healthcare Conference

WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Healthcare Conference in New York on Thursday, June 8, 2023 at 2:00 p.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit , and follow us on , and .

Contact:

Dyne Therapeutics

Amy Reilly



857-341-1203



EN
01/06/2023

Underlying

DYNDyne Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dyne Therapeutics

 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Rec...

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes - - Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 initiated to support potential submission for U.S. Accelerated Approval in H1 2026 - - Registrational Expansion Cohort of DELIVER Trial of DYNE-251 in DMD fully enrolled to support potential submission for U.S. Accelerated Approval in early 2026 - WALTHAM, Mass...

May 8, 2025 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug...

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy - Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned for late 2025 - WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that the European Commiss...

April 24, 2025 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Announces Chief Business Officer and Chief Scientifi...

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments - Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced the appointments of Vikram (Vik) Ranade, PhD, as chief business officer (CBO) and...

April 15, 2025 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule ...

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to three new employees. The awards were approved by Dyne’s Compensation Committee and made as an inducement material to the new employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement ...

April 14, 2025 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule ...

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it has granted inducement equity awards to its newly appointed Chief Financial Officer, Erick J. Lucera. The awards were approved by the Compensation Committee of Dyne and made as an inducement material to Mr. Lucera’s acceptance of employment ...

March 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch